16,725 results match your criteria Hepatology[Journal]


Early Detection of Hepatocellular Carcinoma - Expanding the Utility of Circulating Tumor Markers.

Hepatology 2018 Dec 17. Epub 2018 Dec 17.

Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Jacksonville, FL.

The global prevalence of hepatocellular cancer (HCC) underscores the need for effective strategies that can reduce the burden and impact of this disease. The increase in the incidence and mortality from HCC in the United States and Europe further emphasize the need for early detection to identify tumors at an early stage and amenable to curative treatments Screening and surveillance for HCC in patients with cirrhosis has been shown to improve survival. Guidelines from major professional societies encourage surveillance for HCC in patients with cirrhosis, advanced fibrosis or high risk hepatitis B virus (HBV) infection. Read More

View Article
December 2018

Modulation of Insulin Resistance in NAFLD.

Hepatology 2018 Dec 16. Epub 2018 Dec 16.

National Institute for Health Research Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, and the University of Birmingham.

Non-alcoholic fatty liver disease (NAFLD) has an estimated prevalence of 25% in the general population, and cirrhosis secondary to Non-Alcoholic Steatohepatitis (NASH) is predicted to become the leading cause of liver transplantation and yet there is a lack of effective licensed treatments. There is a close relationship between insulin resistance and NAFLD, with the prevalence of NAFLD being five-fold higher in patients with diabetes compared to patients without. Insulin resistance is implicated both in the pathogenesis of NAFLD and in disease progression from steatosis to NASH. Read More

View Article
December 2018

SIRT4 Depletion Promotes HCC Tumorigenesis through Regulating AMPKα/mTOR Axis.

Hepatology 2018 Dec 15. Epub 2018 Dec 15.

Berkeley Biomedical Data Science Center, Lawrence Berkeley National Laboratory, Berkeley, California, USA.

Sirtuin 4 (SIRT4) has been reported to play a vital role in the maintenance of glutamine catabolism and ATP homeostasis, but its character in hepatocellular carcinomas (HCCs) remains obscure. In this study, we observed low expression of SIRT4 in both HCC cell lines and HCCs from patients. Decreased disease-free survival time is associated with low tumor levels of SIRT4 in patients. Read More

View Article
December 2018

Emergence of oncogenic-enhancing hepatitis B virus X gene mutants in patients receiving suboptimal entecavir treatment.

Hepatology 2018 Dec 15. Epub 2018 Dec 15.

Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan.

Entecavir is a widely used nucleoside analogue for antiviral therapy against chronic hepatitis B virus (HBV) infection. Despite its remarkable efficacy in suppressing HBV replication, a substantial proportion of cirrhotic patients still developed hepatocellular carcinoma (HCC) after entecavir treatment (1). Presumably, it is largely attributed to the existing precancerous hepatocytes, which sturdily progresses into cancer despite effective viral suppression. Read More

View Article
December 2018

PUMA induction mediates acetaminophen-induced necrosis and liver injury.

Hepatology 2018 Dec 14. Epub 2018 Dec 14.

UPMC Hillman Cancer Center, Pittsburgh, PA, 15213, USA.

Acetaminophen (APAP) overdose is one of the leading causes of hepatotoxicity and acute liver failure in the United States. Accumulating evidence suggests that hepatocyte necrosis plays a critical role in APAP-induced liver injury. However, the mechanisms of APAP-induced necrosis and liver injury are not fully understood. Read More

View Article
December 2018

Recurrence of hereditary hemorrhagic telangiectasia after liver transplantation: clinical implications and physiopathological insights.

Hepatology 2018 Dec 14. Epub 2018 Dec 14.

Gustave Roussy Cancer Campus, Département de Biologie et Pathologie Médicales, Service de Pathologie Moléculaire, Villejuif.

Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. We provide a long-term evaluation of graft status after LT for HHT, with a focus on the risk of recurrence. The present study included all patients prospectively followed-up after LT for HHT in the Lyon liver transplant unit from 1993 to 2010, with a survival of more than 1 year. Read More

View Article
December 2018

Improvements in Histologic Features and Diagnosis associated with Improvement in Fibrosis in NASH: Results from the NASH Clinical Research Network Treatment Trials.

Hepatology 2018 Dec 14. Epub 2018 Dec 14.

Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO, 63104.

Hepatocellular injury and inflammation are believed to be the primary drivers of fibrogenesis that ultimately lead to cirrhosis in patients with NASH.

Aim: This study sought associations between observed improvements in fibrosis with improvement in specific histologic features, NAFLD Activity Score (NAS) ≥ 2, diagnostic category, and primary histologically based outcomes of two adult NASH treatment trials. The primary outcome for the study was fibrosis improvement from baseline to end of treatment, defined as a 1 point or more improvement in fibrosis stage. Read More

View Article
December 2018

Pharmacological induction of a progenitor state for the efficient expansion of primary human hepatocytes.

Hepatology 2018 Dec 14. Epub 2018 Dec 14.

School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015, Lausanne, Switzerland.

The liver is an organ with strong regenerative capacity, yet primary hepatocytes have a low amplification potential in vitro, a major limitation for the cell-based therapy of liver disorders and for ex vivo biological screens. Induced pluripotent stem cells (iPSC) may help to circumvent this obstacle, but often harbor genetic and epigenetic abnormalities limiting their potential. Here, we describe the pharmacological induction of proliferative human hepatic progenitor cells (HPC) through a cocktail of growth factors and small molecules mimicking the signaling events involved in liver regeneration. Read More

View Article
December 2018
1 Read

Targeting TGF-β signaling in Liver Cancer.

Hepatology 2018 Dec 14. Epub 2018 Dec 14.

Center for Translational Medicine, Department of Surgery, George Washington University, Washington, DC, 20052.

Hepatocellular carcinoma (HCC), accounting for 85-90% of all primary liver cancers, is among the most prevalent and lethal cancers in the world, with five-year survival for advanced cases under 11%. Ineffective detection of tumors and drug resistance are some of the causal factors for therapy failure. Thus, there is an urgent need to understand the molecular mechanisms underlying drug resistance and HCC initiation. Read More

View Article
December 2018

Entecavir and peginterferon alfa-2a in adults with HBeAg-positive immune tolerant chronic hepatitis B virus infection.

Hepatology 2018 Dec 14. Epub 2018 Dec 14.

University of Michigan.

Background/aim: Monotherapy with interferon or nucleoside analog is generally not recommended during the immune tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase. Small pediatric studies reported efficacy with combination nucleoside analog and interferon therapy. Read More

View Article
December 2018

MicroRNAs: Unfolding the link between inositol-requiring enzyme 1α and fatty liver.

Hepatology 2018 Dec 14. Epub 2018 Dec 14.

Northwestern University Feinberg School of Medicine.

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of abnormal liver chemistry tests in the United States and western world. The mechanisms underlying hepatic steatosis and the progression to nonalcoholic steatohepatitis (NASH) remain incompletely understood. Multiple cellular stress pathways are believed to contribute to the pathogenesis of fatty liver, including endoplasmic reticulum (ER) stress and its adaptive unfolded protein response (UPR). Read More

View Article
December 2018
1 Read

Sofosbuvir and Ribavirin eradication of refractory hepatitis E in an immunosuppressed kidney transplant recipient.

Hepatology 2018 Dec 14. Epub 2018 Dec 14.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Hepatitis E virus (HEV) infection is a self-limited asymptomatic illness in immunocompetent patients, but may cause chronic infection in immunosuppressed, solid organ transplant recipients. Chronic HEV can result in aggressive inflammation and fibrosis, leading to cirrhosis in up to 10%(1). Current therapy has been limited to reducing immunosuppression and/or ribavirin which leads to viral clearance in 64-74% of patients. Read More

View Article
December 2018

Alpha-fetoprotein Decrease from >1000 to <500 ng/ml in Patients with Hepatocellular Carcinoma Leads to Improved Post-Transplant Outcomes.

Hepatology 2018 Dec 13. Epub 2018 Dec 13.

Division of Gastroenterology, Department of Medicine, University of California, San Francisco.

High alpha-fetoprotein (AFP) >1000 ng/ml is associated with poor outcome after liver transplant (LT) for hepatocellular carcinoma (HCC). A new national policy has been implemented for AFP >1000 requiring a decrease to <500 before LT, but there is a paucity of data on the optimal AFP threshold before LT. We aimed to evaluate the effects of a reduction in AFP from >1000 to different AFP thresholds before LT on survival and HCC recurrence after LT using the UNOS database. Read More

View Article
December 2018
1 Read

Cirrhotic Cardiomyopathy in children with BA: A new objective parameter to predict morbidity and mortality on the waitlist - and beyond!

Authors:
Elizabeth B Rand

Hepatology 2018 Dec 12. Epub 2018 Dec 12.

Department of Pediatrics, The Perelman School of Medicine of the University of Pennsylvania.

Pediatric waitlist morbidity and mortality is high overall but unpredictable in individual cases resulting in poor stratification and general dissatisfaction with our current system of liver allocation in infants and children. The scope of this problem is broad but has harshest impact on our youngest candidates who disproportionately suffer from biliary atresia (BA). This article is protected by copyright. Read More

View Article
December 2018

The need for complete population-based studies on the etiology of liver disease.

Authors:
Paulo S Pinheiro

Hepatology 2018 Dec 6. Epub 2018 Dec 6.

University of Miami School of Medicine, Public Health Sciences, 1120 14th NW St., Don Soffer Clinical Research Building, Miami, Florida, United States.

I read Kim et al.'s "Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the US" with great interest. Patterns for hepatocellular carcinoma (HCC) are complex, with disparities likely rooted in etiological differences. Read More

View Article
December 2018
2 Reads

Orchestration of Tryptophan-Kynurenine pathway, acute decompensation and acute-on-chronic liver failure in cirrhosis.

Hepatology 2018 Dec 6. Epub 2018 Dec 6.

EF Clif, EASL-CLIF Consortium and Grifols Chair, Barcelona, Spain.

Systemic inflammation (SI) is involved in the pathogenesis of acute decompensation (AD) and acute-on-chronic liver failure (ACLF) in cirrhosis. In other diseases, SI activates tryptophan (Trp) degradation via the kynurenine pathway (KP), giving rise to metabolites that contribute to multiorgan/system damage and immunosuppression. In the current study, we aimed to characterize the KP in patients with cirrhosis, in whom this pathway is poorly known. Read More

View Article
December 2018
14 Reads

ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Cancer stem cells (CSCs) are well contributing to high rate of recurrence and chemotherapeutic resistance in many types of cancer including intrahepatic cholangiocarcinoma (ICC). Inhibitor of differentiation 3 (ID3) has been reported to promote cancer stem cells, but its role in ICC is obscure. In this study, we identified that ID3 is highly expressed in human ICC tissues compared with matched normal tissues and correlates with poor prognosis. Read More

View Article
December 2018
1 Read

Hepatic Resection Compared to Chemoembolization in Intermediate to Advanced-Stage HCC: a comment for moving forward.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.

Treatment of hepatocellular carcinoma (HCC) depends on disease staging, which is usually performed according to the Barcelona Clinic Liver Cancer (BCLC) system. Although the BCLC system is recommended in the guidelines from the European Association for the Study of the Liver, the American Association for the Study of Liver Diseases, and the European Society for Medical Oncology , its treatment recommendations for intermediate and advanced HCC are inconsistent with the literature. This article is protected by copyright. Read More

View Article
December 2018
4 Reads

Stereotactic radiofrequency ablation of hepatocellular carcinoma - A histopathological study in explanted livers.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

INNPATH, Institute of Pathology, Tirol Kliniken Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria.

Background And Rationale For The Study: This retrospective study was performed to evaluate the efficacy of 3D-navigated multi-probe radiofrequency ablation (RFA) with intraprocedural image fusion for the treatment of hepatocellular carcinoma (HCC) by histopathologic examination.

Main Results: From 2009 to 2018, 97 patients (84 men, 13 women; median age 60 years, range 1 -71) were transplanted after bridging therapy of 195 HCCs by stereotactic RFA (SRFA). The median interval between the first SRFA and transplantation was 6. Read More

View Article
December 2018
1 Read

Hepatocyte Nuclear Factor 4 alpha (HNF4α) Activation is Essential for Termination of Liver Regeneration.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

Department of Pharmacology, Toxicology and Therapeutics.

Hepatocyte Nuclear Factor 4 alpha (HNF4α) is critical for hepatic differentiation. Recent studies have highlighted its role in inhibition of hepatocyte proliferation and tumor suppression. However, the role of HNF4α in liver regeneration is not known. Read More

View Article
December 2018
4 Reads

The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.

Nonalcoholic fatty liver disease (NAFLD), the most common form of chronic liver disease, exists in two predominant histological subtypes: nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). NASH is the clinically aggressive variant with higher risk of fibrosis progression and mortality. The leading cause of mortality in patients with NAFLD is cardiovascular disease (CVD), and is linked to diagnosis of NASH and severity of hepatic fibrosis. Read More

View Article
December 2018
10 Reads

Hepatic Autophagy Deficiency Compromises FXR Functionality and Causes Cholestatic Injury.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Autophagy is important for hepatic homeostasis, nutrient regeneration and organelle quality control. We investigated the mechanisms by which liver injury occurred in the absence of autophagy function. We found that mice deficient in autophagy due to the lack of Atg7 or Atg5, key autophagy-related genes, manifested intracellular cholestasis with increased levels of serum bile acids, a higher ratio of TMCA/TCA in the bile, increased hepatic bile acid load, abnormal bile canaliculi and altered expression of hepatic transporters. Read More

View Article
December 2018
4 Reads

Peribiliary glands are key in regeneration of the human biliary epithelium after severe bile duct injury.

Hepatology 2018 Dec 2. Epub 2018 Dec 2.

Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Peribiliary glands (PBG) are a source of stem/progenitor cells organized in a cellular network encircling large bile ducts. Severe cholangiopathy with loss of luminal biliary epithelium has been proposed to activate PBG, resulting in cell proliferation and differentiation to restore biliary epithelial integrity. However, formal evidence for this concept in human livers is lacking. Read More

View Article
December 2018
1 Read

Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis.

Hepatology 2018 Dec 1. Epub 2018 Dec 1.

Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, U.S.

Vitamin E improves liver histology in non-diabetic adults with nonalcoholic steatohepatitis (NASH), but its impact on long-term patient outcomes is unknown. We evaluated whether vitamin E treatment improves clinical outcomes of NASH patients with bridging fibrosis or cirrhosis. Two hundred and thirty-six patients with biopsy-proven NASH and bridging fibrosis or cirrhosis seen at Indiana University Medical Center between October 2004, and January 2016 were included. Read More

View Article
December 2018
2 Reads

Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice.

Hepatology 2018 Dec 1. Epub 2018 Dec 1.

Department of Intensive Care Unit, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

Sepsis-induced liver injury is recognized as a key problem in intensive care units (ICUs). The gut microbiota has been touted as an important mediator of liver disease development; however, the precise roles of gut microbiota in regulating sepsis-induced liver injury are unknown. Here, we aimed to investigate the role of the gut microbiota in sepsis-induced liver injury and the underlying mechanism. Read More

View Article
December 2018
1 Read
11.055 Impact Factor

Liver stiffness in non-cirrhotic portal hypertension - The Devil is in the diagnosis.

Hepatology 2018 Dec 1. Epub 2018 Dec 1.

Dept. of Clinical Medicine, "Sapienza" University of Rome, Rome, Italy.

We have read with great interest the article by Vuppalanchi et al. , who studied the diagnostic role of liver stiffness measurements (LSM) in patients with non-cirrhotic portal hypertension (NCPH) due to hepatic (nodular regenerative hyperplasia-NRH) or prehepatic origin (portal vein thrombosis-PVT). The role of LSM to identify a cirrhosis as the cause of the portal hypertension is well established and the evidence of PVT in any imaging technique is sufficient to attribute the cause of portal hypertension to PVT and does not require further histological or elastographical confirmation. Read More

View Article
December 2018
3 Reads

Cannabinoid-1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure via Sirt1/mTORC2 and AMPK Signaling.

Hepatology 2018 Dec 1. Epub 2018 Dec 1.

Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, 20892.

Endocannabinoids promote energy conservation in obesity, whereas cannabinoid-1 receptor (CB R) blockade reverses body weight gain and insulin resistance and increases energy expenditure. Here we investigated the molecular mechanisms of the catabolic effects of CB R blockade in the liver. Exposure of primary mouse hepatocytes and HepG2 cells to the CB R agonist ACEA inhibited the expression of Sirt1 and Rictor, a component of mTORC2, and suppressed insulin-induced Akt phosphorylation at ser473. Read More

View Article
December 2018
1 Read

Vessels that encapsulate tumor clusters (VETC) pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma.

Hepatology 2018 Dec 1. Epub 2018 Dec 1.

MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.

Sorafenib is the most recommended first-line systemic therapy for advanced hepatocellular carcinoma (HCC). Yet there is no clinically applied biomarker for predicting sorafenib response. We have demonstrated that a vascular pattern, named VETC (vessels that encapsulate tumor clusters), facilitates the release of whole tumor clusters into the bloodstream; VETC-mediated metastasis relies on vascular pattern but not on the migration and invasion of cancer cells. Read More

View Article
December 2018
11 Reads

Dietary patterns and risk of hepatocellular carcinoma among US men and women.

Hepatology 2018 Dec 1. Epub 2018 Dec 1.

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and, Harvard Medical School, Boston, MA, USA.

Although adherence to healthy dietary guidelines has been associated with a reduced risk of several health outcomes including cardiovascular diseases, type 2 diabetes, and some cancers, little is known about the role of dietary patterns in the development of hepatocellular carcinoma. We prospectively assessed the associations of 3 key commonly used a priori dietary patterns, the Alternative Healthy Eating Index-2010 (AHEI-2010), Alternate Mediterranean Diet (AMED), and Dietary Approaches to Stop Hypertension (DASH) with risk of incident hepatocellular carcinoma in the Health Professionals Follow-up Study and the Nurses' Health Study, two large prospective cohort studies. Diet was assessed almost every 4 years using validated food frequency questionnaires. Read More

View Article
December 2018
3 Reads

Management of Sepsis in Patients with Cirrhosis: current evidence and practical approach.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

Division of Gastroenterology and Hepatology.

Sepsis in patients with cirrhosis is associated with high mortality. An impaired immune response accounts for the increased infection risk observed in these patients. Hemodynamic and systemic changes suggestive of sepsis may be seen in patients with cirrhosis in the absence of infection, therefore diagnosis and treatment of sepsis may be delayed. Read More

View Article
December 2018
1 Read

HELLS regulates chromatin remodeling and epigenetic silencing of multiple tumor suppressor genes in human hepatocellular carcinoma.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

Department of Pathology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong.

Hepatocellular carcinoma (HCC) is the third lethal cancer worldwide. Increasing evidence showed that epigenetic alterations play an important role in human carcinogenesis. Deregulation of DNA methylation and histone modifications have recently been characterized in HCC, but the significance of chromatin remodeling in liver carcinogenesis remains to be explored. Read More

View Article
December 2018
5 Reads

Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids into Triglyceride Biosynthesis.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

Joan & Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, 10021, USA.

In non-alcoholic fatty liver disease (NAFLD), triglycerides accumulate within the liver because the rates of fatty acid accrual by uptake from plasma and de novo synthesis exceed elimination by mitochondrial oxidation and secretion as VLDL-triglycerides. Thioesterase superfamily member 2 (Them2) is an acyl-CoA thioesterase that catalyzes the hydrolysis of fatty acyl-CoAs into free fatty acids plus CoASH. Them2 is highly expressed in the liver, as well as other oxidative tissues. Read More

View Article
December 2018
5 Reads

Dietary Lipids Differentially Shape NASH Progression and the Transcriptome of Kupffer Cells and Infiltrating Macrophages.

Hepatology 2018 Dec 5. Epub 2018 Dec 5.

Department of Medicine, University of Colorado, Denver Division of Gastroenterology & Hepatology.

Background: A crucial component of non-alcoholic fatty liver disease (NAFLD) pathogenesis is lipid stress, which may contribute to hepatic inflammation and activation of innate immunity in the liver. However, little is known regarding how dietary lipids, including fat and cholesterol, may facilitate innate immune activation in vivo. We hypothesized that dietary fat and cholesterol drive NAFLD progression to steatohepatitis and hepatic fibrosis by altering the transcription and phenotype of hepatic macrophages METHODS: This hypothesis was tested by using RNA-seq methods to characterize and analyze sort-purified hepatic macrophage populations that were isolated from mice fed diets with varying amounts of fat and cholesterol RESULTS: The addition of cholesterol to a high fat diet triggered hepatic pathology reminiscent of advanced non-alcoholic steatohepatitis (NASH) in humans characterized by signs of cholesterol dysregulation, generation of oxidized LDL, increased recruitment of hepatic macrophages, and significant fibrosis. Read More

View Article
December 2018
5 Reads

Gallstone disease and type 2 diabetes risk: A Mendelian randomization study.

Hepatology 2018 Dec 4. Epub 2018 Dec 4.

Department of Occupational and Environmental Health and Key Laboratory of Environmental and Health, Ministry of Education & Ministry of Environmental Protection, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, P.R. China.

Presence of gallstone disease (GSD) was reported to be positively associated with diabetes risk. Whether the association is causal remains unclear. We aim to examine the potential causal association between GSD and type 2 diabetes risk using a Mendelian randomization analysis. Read More

View Article
December 2018
4 Reads
11.055 Impact Factor

Refining non-invasive diagnostics in NAFLD - closing the gap to detect advanced fibrosis.

Hepatology 2018 Dec 4. Epub 2018 Dec 4.

NAFLD Research Center, Division of Gastroenterology, University of California San Diego School of Medicine, San Diego, CA, 92093-0887.

The epidemic of non-alcoholic fatty liver disease (NAFLD) has created a large demand for diagnostic tools to identify patients at risk of disease progression including the development of end-stage liver disease. The prevalence of NAFLD is rising worldwide and it is estimated that approximately 1 billion individuals may be afflicted with NAFLD globally (1). Currently, the gold standard to diagnose advanced fibrosis and therefore the reference for all non-invasive technology is liver histology and it's assessment by an experienced liver-histopathologist. Read More

View Article
December 2018
7 Reads

Corrections.

Authors:

Hepatology 2018 Dec;68(6):2445

View Article
December 2018

2018 HEPATOLOGY Referees (Volumes 67 and 68).

Authors:

Hepatology 2018 Dec;68(6):2446-2452

View Article
December 2018

Corrections.

Authors:

Hepatology 2018 Dec;68(6):2445

View Article
December 2018

Patient-reported outcomes for NAFLD/NASH: rational for expanded use.

Hepatology 2018 Nov 25. Epub 2018 Nov 25.

Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain.

It is estimated that one in four adults around the world has non-alcoholic fatty liver disease (NAFLD), a condition that can lead to non-alcoholic steatohepatitis (NASH), serious liver damage and, ultimately, death. The arrival of new treatment options and prevention strategies for NAFLD/NASH will result in an increasing number of clinical trials targeting this disease. Younossi outlined (1) the increasing importance of including patient-reported outcomes (PROs) in future clinical trials for NAFLD/NASH treatment. Read More

View Article
November 2018
7 Reads

Diagnosis and treatment of alcohol use disorder in patients with end-stage alcoholic liver disease.

Hepatology 2018 Nov 24. Epub 2018 Nov 24.

"G. Fontana" Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Medical and Surgical Sciences, University of Bologna, Italy.

Almost 14-30% of the world's population is affected by alcohol use disorder (AUD), and excessive alcohol consumption represents the most common cause of liver disease in the western world. The clinical picture of alcoholic end-stage liver disease is rendered extremely complex as manifestations such as alcohol withdrawal syndrome, craving and physical dependence, as well as extrahepatic alcohol-related diseases merge with the complications of advanced cirrhosis. This makes AUD recognition and assessment difficult and its management arduous as many drugs commonly employed to treat complications such as alcohol withdrawal syndrome are often contraindicated by the presence of hepatic encephalopathy or hepatorenal syndrome. Read More

View Article
November 2018
7 Reads

Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: Review of pathogenesis and management.

Hepatology 2018 Nov 23. Epub 2018 Nov 23.

Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.

Healthy sexual function is important to maintain a good quality of life but is frequently impaired in patients with cirrhosis. The degree of sexual dysfunction appears to be linked with the degree of hepatic dysfunction. In men, sexual dysfunction can be related to the hyperestrogenism of portal hypertension and/or to decreased testosterone resulting from testicular dysfunction. Read More

View Article
November 2018
2 Reads

New strategies for the management of decompensated cirrosis: long-term albumin administration for everyone?

Hepatology 2018 Nov 23. Epub 2018 Nov 23.

Liver Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.

Natural history of cirrhosis is characterized by the progression from a compensated to a decompensated state, which is defined by the development of several complications of the disease (1). Ascites is the most frequent complication of patients with decompensated cirrhosis, but other common complications include hepatic encephalopathy, GI bleeding, bacterial infections, kidney failure and hyponatremia. Decompensated cirrhosis is not only associated with poor outcome, with median survival of approximately 2 years, but also with impaired health-related quality of life and high economic burden due to frequent hospital admissions and use of health-care resources. Read More

View Article
November 2018
1 Read

HSD17B13 is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non-Alcoholic Fatty Liver Disease.

Hepatology 2018 Nov 11. Epub 2018 Nov 11.

Liver and Energy Metabolism Unit.

Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. A single nucleotide polymorphism (SNPs), rs6834314, was associated with serum liver enzymes in the general population, presumably reflecting liver fat or injury. We studied rs6834314 and its nearest gene, HSD17B13 (17-beta hydroxysteroid dehydrogenase 13) to identify associations with histological features of NAFLD, and to characterize the functional role of HSD17B13 in NAFLD pathogenesis. Read More

View Article
November 2018
15 Reads

Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis.

Hepatology 2018 Nov 10. Epub 2018 Nov 10.

Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Alcalá de Henares, Spain.

In cirrhosis, intestinal dysbiosis, intestinal barrier impairment and systemic immune system abnormalities lead to gut bacterial translocation (GBT) and bacterial infection. However, intestinal immune system dysfunction and its contribution to barrier damage are poorly understood. This study correlates immune system dysregulation in the intestines of rats at different stages of CCl -induced cirrhosis with barrier function and pathogenic microbiota. Read More

View Article
November 2018
10 Reads

The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis.

Hepatology 2018 Nov 8. Epub 2018 Nov 8.

Hepatology Program. Cima, University of Navarra, Pamplona, Spain.

Intrahepatic accumulation of bile acids (BA) causes hepatocellular injury. Upon liver damage, a potent protective response is mounted to restore the organ's function. Epidermal growth factor receptor (EGFR) signaling is essential for regeneration after most types of liver damage, including cholestatic injury. Read More

View Article
November 2018
4 Reads
11.055 Impact Factor

Human CD96 correlates to NK cell exhaustion and predicts the prognosis of human hepatocellular carcinoma.

Hepatology 2018 Nov 8. Epub 2018 Nov 8.

Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, China.

Immune checkpoint blockade has become a promising therapeutic approach to reverse immune cell exhaustion. Co-inhibitory CD96 and TIGIT, together with co-stimulatory CD226, bind to common ligand CD155. The balancing between three receptors fine tunes the immune responses against tumors. Read More

View Article
November 2018
13 Reads

Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.

Hepatology 2018 Nov 6. Epub 2018 Nov 6.

Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA.

Hepatitis C virus (HCV) infection is the most commonly reported bloodborne infection in the United States, causing substantial morbidity and mortality and costing billions of dollars annually. To update the estimated HCV prevalence among all adults aged ≥18 years in the United States, we analyzed 2013-2016 data from the National Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of HCV in the noninstitutionalized civilian population and used a combination of literature reviews and population size estimation approaches to estimate the HCV prevalence and population sizes for four additional populations: incarcerated people, unsheltered homeless people, active-duty military personnel, and nursing home residents. We estimated that during 2013-2016 1. Read More

View Article
November 2018
7 Reads

A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC.

Hepatology 2018 Nov 5. Epub 2018 Nov 5.

Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, 23298, USA.

Hepatocellular carcinoma (HCC) is increasing as a cause of liver-related mortality largely due to the growing burden of nonalcoholic steatohepatitis (NASH). The mechanisms of HCC development in nonalcoholic fatty liver disease (NAFLD) are incompletely understood. We initially identified apoptosis antagonizing transcription factor (AATF) to be associated with HCC in a mouse model of NASH that develops HCC without the addition of specific carcinogens. Read More

View Article
November 2018
16 Reads

Immunosuppression minimization trials in liver transplantation: can we predict humoral response to asses eligibility?

Hepatology 2018 Nov 5. Epub 2018 Nov 5.

CHU Saint Eloi, Département d'hépatologie et transplantation hépatique, Montpellier, France.

We have read with great interest the article by Jucaud et al. (1) reporting that de novo donor-specific HLA antibodies (dnDSA) development during immunosuppression (IS) withdrawal in liver transplantation (LT) was associated with acute rejection and prevented further attempts of IS withdrawal. This article is protected by copyright. Read More

View Article
November 2018
11.050 Impact Factor